Skip to content

Abivax

  • EN
  • FR
  • About Abivax
    • Our Mission
    • Company History
    • Our Leadership
    • Contact Us
  • Our Science
    • Novel MOA
    • Obefazimod
  • Our Research
  • Our Pipeline
  • Publications
  • Investors
    • Overview
    • Press Releases
    • News
    • Share Price
    • Investor Documents
    • General Meeting
    • Corporate Presentation
  • EN
  • FR

News & Events

Press Coverage

  • 2023
  • 2022
  • 2021
  • 2020
  • 2019

4investors

June 23, 2021

Abivax: ABX464 mit starken Studiendaten in der Behandlung Rheumatoider Arthritis

Scrip

June 23, 2021

AbiVax’s Partnering Prospects For MicroRNA-based Drug Boosted By Rheumatoid Arthritis Data

BioSpace

May 27, 2021

Global Roundup: Abivax Eyes Phase III Following Positive UC Data

The PharmaLetter

May 26, 2021

Abivax reports excellent efficacy and safety of ABX464 in Phase IIb

PharmaTimes

May 26, 2021

Abivax’s ABX464 shows ‘impressive’ efficacy in severe ulcerative colitis patients

  • 1
  • 2
  • 3
  • 4
  • …
  • 7

References available upon request.

© 2025 All rights reserved by Abivax 07/2024 Privacy and Terms of Use
Consent Preferences
  • About Abivax
    • Our Mission
    • Company History
    • Our Leadership
    • Contact Us
  • Our Science
    • Novel MOA
    • Obefazimod
  • Our Research
  • Our Pipeline
  • Publications
  • Investors
    • Overview
    • Press Releases
    • News
    • Share Price
    • Investor Documents
    • General Meeting
    • Corporate Presentation
Contact Us
  • Follow us on Twitter
  • Follow us on LinkedIn